Yahoo
NSE - Delayed Quote INR

AKUMS DRUGS AND PHARMA L (AKUMS.NS)

751.85 +1.90 (+0.25%)
At close: 3:29:58 PM GMT+5:30
Chart Range Bar
Loading chart for AKUMS.NS
  • Previous Close 749.95
  • Open 756.00
  • Bid --
  • Ask --
  • Day's Range 746.00 - 759.75
  • 52 Week Range 409.30 - 769.45
  • Volume 287,649
  • Avg. Volume 383,383
  • Market Cap (intraday) 115.11B
  • Beta (5Y Monthly) 0.55
  • PE Ratio (TTM) 39.53
  • EPS (TTM) 19.02
  • Earnings Date --
  • Forward Dividend & Yield 1.00 (0.13%)
  • Ex-Dividend Date Jul 3, 2026
  • 1y Target Est 780.00

Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, and gummies for therapeutic areas, such as antiinfectives, pain management, gastroenterology, orthopaedics, cardio-diabetic care, critical care, respiratory, and gynaecology. In addition, the company operates as pharmaceutical contract development and manufacturing company. Akums Drugs and Pharmaceuticals Limited was incorporated in 2004 and is based in Delhi, India.

www.akums.in

7,337

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 8/13/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

AKUMS.NS
66.61%
S&P BSE SENSEX (^BSESN)
8.38%

1-Year Return

AKUMS.NS
54.92%
S&P BSE SENSEX (^BSESN)
3.05%

3-Year Return

AKUMS.NS
3.70%
S&P BSE SENSEX (^BSESN)
19.53%

5-Year Return

AKUMS.NS
3.70%
S&P BSE SENSEX (^BSESN)
40.84%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 11.67B
Earnings 1B

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
2B
4B
6B
8B
10B

Analyst Insights

View More

Analyst Price Targets

610.00 Low
780.00 Average
751.85 Current
880.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
As of 8/10/2026
  • Market Cap

    116.51B

  • Enterprise Value

    101.62B

  • Trailing P/E

    38.33

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.54

  • Price/Book (mrq)

    3.37

  • Enterprise Value/Revenue

    2.21

  • Enterprise Value/EBITDA

    14.39

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.48%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    45.04B

  • Net Income Avi to Common (ttm)

    2.92B

  • Diluted EPS (ttm)

    19.02

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    16.81B

  • Total Debt/Equity (mrq)

    5.76%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: